Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Maribel Rodriguez-Torres"'
Autor:
Maribel Rodriguez-Torres, Eric Läwitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J. Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M. Vierling, Velimir Luketic, Philippe J. Zamor, Natarajan Ravendhran, Timothy R. Morgan, Brian Pearlman, Christopher O’Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D. Yin, Eric Hughes, Michelle Treitel
Publikováno v:
Annals of Hepatology, Vol 15, Iss 6, Pp 834-845 (2016)
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and w
Externí odkaz:
https://doaj.org/article/758320977acf45fe990b1d476981cdbb
Autor:
Maribel Rodriguez-Torres, Eric M. Yoshida, Patrick Marcellin, Subasree Srinivasan, Vivek S. Purohit, Cunshan Wang, Jennifer L. Hammond, Ph.D.
Publikováno v:
Annals of Hepatology, Vol 13, Iss 4, Pp 364-375 (2014)
Objectives. Filibuvir is a non-nucleoside inhibitor of hepatitis C virus (HCV) polymerase. This study evaluated the safety and efficacy of filibuvir plus pegylated interferon alfa-2a (pegIFN)/ribavirin.Material and methods. Treatment-naïve, HCV geno
Externí odkaz:
https://doaj.org/article/6f954e6b89a54326b802d03c0f1bee31
Autor:
Nahum Méndez-Sánchez, Adrian Gadano, Angelo Alves de Mattos, Alejandro Soza, Augusto Marroni Claudio, Marcela Galoppo, David Kershenobich, Edna Strauss, Eduardo Fassio, Gilberto Castañeda, Guillermo Valladares, Henrique Sergio Moraes Coelho, Jorge Daruich, Miguel Garassini, Milagros Dávalos, Misael Uribe, Maribel Rodriguez-Torres, Rodrigo Zapata, Marco Arrese, Francisco Sánchez-Ávila, Margarita Dehesa, Francisco Bosques Padilla, Paulo Roberto Lerias de Almeida, Mario Pessoa, Rocío Torres-Ibarra, Francisco Hevia, Miguel Contreras, Hugo Cheinquer
Publikováno v:
Annals of Hepatology, Vol 9, Iss , Pp S8-S26 (2010)
Externí odkaz:
https://doaj.org/article/72c838a6a1d148f0bbb50af7e0bf5bd0
Autor:
Christopher Hartl, Katherine Tooley, Laura Riba, David Torrents, Ulises Alvirde, Olimpia Arellano-Campos, Ralph A. DeFronzo, Taru Tukiainen, Geoffrey A. Walford, Noël P. Burtt, Donna M. Lehman, Amy L. Williams, Alicia Huerta-Chagoya, Pierre Fontanillas, Richa Saxena, Stacey Gabriel, Michael Boehnke, Carlos A. Aguilar-Salinas, Stephan Ripke, Yayoi Segura-Kato, Steven A. McCarroll, Jacqueline M. Lane, Brian E. Henderson, Ravindranath Duggirala, Sobha Puppala, Ignasi Moran, Humberto García-Ortiz, Lizz Caulkins, María Elena González-Villalpando, Vineeta Agarwala, Maria L. Cortes, Jorge Ferrer, Cristina Revilla-Monsalve, Graeme I. Bell, Jason Flannick, Francisco Barajas-Olmos, María Luisa Ordóñez-Sánchez, Angélica Martínez-Hernández, Robert L. Hanson, Jose C. Florez, Broad Genomics Platform, Clicerio González-Villalpando, Ivette Cruz-Bautista, Rosario Rodríguez-Guillén, Sílvia Bonàs-Guarch, Rachel G. Liao, Lorena Orozco, Kathleen A. Jablonski, Daniel G. MacArthur, Elvia Mendoza-Caamal, Emilio J. Cordova, Karol Estrada, Hortensia Moreno-Macías, Leslie J. Baier, Avery Davis Bell, Hanna E. Abboud, Suzanne B.R. Jacobs, Maribel Rodriguez-Torres, Xavier Soberón, William C. Knowler, David Altshuler, Zachary Dymek, Christopher A. Haiman, Josep M. Mercader, Donaji V. Gómez-Velasco, Liliana Muñoz-Hernandez, Joanne E. Curran, Loic Le Marchand, Maegan Harden, Lynne R. Wilkens, John Blangero, Teresa Tusié-Luna, Federico Centeno-Cruz, Ling Chen, Craig L. Hanis, Carlos Zerrweck, Sergio Islas-Andrade, Cecilia Contreras-Cubas, Christopher P. Jenkinson
Publikováno v:
Diabetes. 66:2903-2914
Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d58bd10df5e8a8fa75529f2b8410f28
https://doi.org/10.2337/db17-0187
https://doi.org/10.2337/db17-0187
Autor:
K. Sims, Shu-Pang Huang, James M. Levin, David F. Gardiner, Vinod K. Rustgi, Tarek Hassanein, Zobair M. Younossi, Federico Hinestrosa, Gregory T. Everson, Trevor Hawkins, Norman Gitlin, Maribel Rodriguez-Torres, Howard J. Schwartz, Timothy Eley, Tadesse Desta, Dennis M. Grasela, Lynn R. Webster, Fiona McPhee, Paul J. Thuluvath, Eric Lawitz
Publikováno v:
Liver International. 36:189-197
Background and Aims This phase-2b study examined the safety and efficacy of an all-oral, interferon-free combination of the NS5A replication complex inhibitor daclatasvir (DCV), the NS3 protease inhibitor asunaprevir (ASV), and the nonnucleoside NS5B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d0c426a693b26202260f5e9abb72c54
https://doi.org/10.1111/liv.12964
https://doi.org/10.1111/liv.12964
Autor:
Greg Sullivan, Prajakta S. Badri, Yiran Hu, Campbell Andrew L, Maribel Rodriguez-Torres, Tami Pilot-Matias, Michael J. Bennett, Mudra Kapoor, Regis A. Vilchez, Fred Poordad, Eric Lawitz, Lino Rodrigues
Publikováno v:
Journal of Infection. 70(2):197-205
SummaryObjectivesTo examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir (ABT-450/r) ± ribavirin (RBV) in treatment-naïve, non-cirrhotic adults with chronic HCV genotype 1–3 infection.MethodsPatients in this open-label, explor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8726cbe4466a45b7582ec0af6b638a41
Autor:
Andrew J, Muir, Sanjeev, Arora, Gregory, Everson, Robert, Flisiak, Jacob, George, Reem, Ghalib, Stuart C, Gordon, Todd, Gray, Susan, Greenbloom, Tarek, Hassanein, Jan, Hillson, Maria Arantxa, Horga, Ira M, Jacobson, Lennox, Jeffers, Kris V, Kowdley, Eric, Lawitz, Stefan, Lueth, Maribel, Rodriguez-Torres, Vinod, Rustgi, Lynn, Shemanski, Mitchell L, Shiffman, Subasree, Srinivasan, Hugo E, Vargas, John M, Vierling, Dong, Xu, Juan C, Lopez-Talavera, Stefan, Zeuzem, Boris, Yoffe
Publikováno v:
Journal of Hepatology. 61:1238-1246
Background & Aims Peginterferon lambda-1a (Lambda) is a type-III interferon with similar antiviral activity to alfa interferons but with a diminished extrahepatic receptor distribution, reducing the risk for extrahepatic adverse events. Methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15d3c4c866b724728fa9279fa51a972a
https://doi.org/10.1016/j.jhep.2014.07.022
https://doi.org/10.1016/j.jhep.2014.07.022
Autor:
Brian L. Pearlman, Joseph K. Lim, Reem Ghalib, John D. Scott, Katleen Callewaert, Ana Corregidor, Sivi Ouwerkerk-Mahadevan, Karen L Lindsay, Ira M. Jacobson, Eric Lawitz, Zobair M. Younossi, Gaston Picchio, Mark S. Sulkowski, Paul J. Pockros, Norman Gitlin, Maria Beumont, Maribel Rodriguez-Torres, Edwin DeJesus, William T. Symonds, Bart Fevery, Tom Lambrecht, Mordechai Rabinovitz
Publikováno v:
The Lancet. 384:1756-1765
Summary Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. Methods We enrolled patients with chronic HCV genotype 1 infections who had previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::385b40febee2f476c15c3bbaea959d58
https://doi.org/10.1016/s0140-6736(14)61036-9
https://doi.org/10.1016/s0140-6736(14)61036-9
Autor:
Eric Lawitz, Anuj Gaggar, Maribel Rodriguez-Torres, Lynn R. Webster, Anh Hoa Nguyen, Thomas Marbury, Stefan Pflanz, Ira M. Jacobson, D. Gruener, J. Hill, Erik Mogalian, Benedetta Massetto, Bradley Freilich, G. Mani Subramanian, John G. McHutchison, David Hassman
Publikováno v:
Antiviral Therapy. 20:699-708
Background GS-9620 is a potent oral agonist of toll-like receptor 7, a key modulator of the innate immune response. In healthy volunteers, low doses of GS-9620 (2, 4 and 6 mg) induced significant expression of peripheral interferon-stimulated-gene (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::263a087ab577c2289d1943cd9e5ff6b6
https://doi.org/10.3851/imp2845
https://doi.org/10.3851/imp2845
Autor:
Vivek S. Purohit, Maribel Rodriguez-Torres, Eric M. Yoshida, Patrick Marcellin, Jennifer Hammond, Subasree Srinivasan, Cunshan Wang
Publikováno v:
Annals of Hepatology, Vol 13, Iss 4, Pp 364-375 (2014)
Objectives. Filibuvir is a non-nucleoside inhibitor of hepatitis C virus (HCV) polymerase. This study evaluated the safety and efficacy of filibuvir plus pegylated interferon alfa-2a (pegIFN)/ribavirin. Material and methods. Treatment-naive, HCV geno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b17151da183071d732f08cd20181887e
https://doi.org/10.1016/s1665-2681(19)30843-9
https://doi.org/10.1016/s1665-2681(19)30843-9